MA29729B1 - USE OF 4- (3,4-DICHLOROPHENYL) -1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE FOR THE TREATMENT OF CANCER - Google Patents

USE OF 4- (3,4-DICHLOROPHENYL) -1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE FOR THE TREATMENT OF CANCER

Info

Publication number
MA29729B1
MA29729B1 MA30615A MA30615A MA29729B1 MA 29729 B1 MA29729 B1 MA 29729B1 MA 30615 A MA30615 A MA 30615A MA 30615 A MA30615 A MA 30615A MA 29729 B1 MA29729 B1 MA 29729B1
Authority
MA
Morocco
Prior art keywords
treatment
ylamine
naphthalen
dichlorophenyl
tetrahydro
Prior art date
Application number
MA30615A
Other languages
French (fr)
Inventor
Frederic Revah
Fabrice Balavoine
Marius Tuijnder
Robert Amson
Adam Telerman
Original Assignee
Anceris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anceris filed Critical Anceris
Publication of MA29729B1 publication Critical patent/MA29729B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UTILISATION DE LA 4-(3,4-DICHLORO-PHÉNYL)-L,2,3,4-TÉTRAHYDRO-NAPHTALÈN-1-YLAMINE OU DE TOUTE COMBINAISON DE SES ÉNANTIOMÈRES OU D'UN DE SES ÉNANTIOMÈRES POUR LA PRÉPARATION D'UNE COMPOSITION PHARMACEUTIQUE DESTINÉE AU TRAITEMENT DU CANCER, AINSI QU'AU TRAITEMENT ET À LA PRÉVENTION DES MÉTASTASES.USE OF 4- (3,4-DICHLOROPHENYL) -L, 2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE OR ANY COMBINATION OF ITS ENANTIOMERS OR ONE OF ITS ENANTIOMERS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER, AND FOR THE TREATMENT AND PREVENTION OF METASTASES.

MA30615A 2005-07-12 2008-02-01 USE OF 4- (3,4-DICHLOROPHENYL) -1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE FOR THE TREATMENT OF CANCER MA29729B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0507480A FR2888506A1 (en) 2005-07-12 2005-07-12 USE OF 4- (3,4-DICHLOROPHENYL) -1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
MA29729B1 true MA29729B1 (en) 2008-09-01

Family

ID=35925210

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30615A MA29729B1 (en) 2005-07-12 2008-02-01 USE OF 4- (3,4-DICHLOROPHENYL) -1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE FOR THE TREATMENT OF CANCER

Country Status (14)

Country Link
EP (1) EP1904045A1 (en)
JP (1) JP2009501193A (en)
KR (1) KR20080031748A (en)
CN (1) CN101222917A (en)
AU (1) AU2006268657A1 (en)
CA (1) CA2614696A1 (en)
FR (1) FR2888506A1 (en)
IL (1) IL188685A0 (en)
MA (1) MA29729B1 (en)
NO (1) NO20080722L (en)
RU (1) RU2008101268A (en)
TN (1) TNSN08010A1 (en)
WO (1) WO2007006797A1 (en)
ZA (1) ZA200800500B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2816024B8 (en) * 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
FR2909283A1 (en) * 2006-11-30 2008-06-06 Cerep Sa COMBINATION PRODUCT CONTAINING N-DESMETHYLSERTRALINE, OR ONE OF ITS SALT, AND AN ANNEOPLASTIC AGENT FOR THE TREATMENT OF CANCER
FR3071726B1 (en) * 2017-09-29 2020-09-04 Univ Paris Sud TCTP PROTEIN INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022085A1 (en) * 1995-01-17 1996-07-25 Pfizer Inc. The use of sertraline to treat cancer patients
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
CA2536340A1 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia

Also Published As

Publication number Publication date
CA2614696A1 (en) 2007-01-18
IL188685A0 (en) 2008-12-29
FR2888506A1 (en) 2007-01-19
TNSN08010A1 (en) 2009-07-14
AU2006268657A1 (en) 2007-01-18
JP2009501193A (en) 2009-01-15
WO2007006797A1 (en) 2007-01-18
EP1904045A1 (en) 2008-04-02
WO2007006797A8 (en) 2007-04-19
RU2008101268A (en) 2009-08-20
CN101222917A (en) 2008-07-16
NO20080722L (en) 2008-04-04
KR20080031748A (en) 2008-04-10
ZA200800500B (en) 2009-04-29

Similar Documents

Publication Publication Date Title
MA30462B1 (en) ANTAGONIST PYRIDYLAMIDE COMPOUNDS OF T-TYPE CALCIUM CHANNELS
MA29378B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-CARBOXYARYL-SUBSTITUTED DIPHENYLUREE FOR THE TREATMENT OF CANCER
MA52488B1 (en) RIP1 INHIBITORY COMPOUNDS AND METHODS OF MAKING AND USING THEM
MA32684B1 (en) Picolinamide derivatives act as kinase inhibitors
NO20060328L (en) Combination of mGluR2 antagonist and ACHE inhibitor for the treatment of acute and / or chronic neurological disorders
ATE509019T1 (en) BENZODIAZEPINE PIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS
FR2869229A1 (en) USE OF A INDUCER OF UGT BY TOPIC
FR16C0021I2 (en) AZETIDINES AS MEK INHIBITORS AND THEIR USE FOR THE TREATMENT OF PROLIFERATIVE DISEASES
TNSN01053A1 (en) NOVEL COMPOSITIONS COMPRISING A PARTIAL NICOTINE RECEPTOR AGONIST AND AN ANALGESIC AGENT
MA29723B1 (en) COMPOUNDS
ATE394400T1 (en) BICYCLIC ANILIDE SPIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS
WO2004082602A3 (en) Carboxamide spirohydantoin cgrp receptor antagonists
MA45811A (en) METHODS AND COMPOSITIONS OF TREATMENT OF DISEASE.
MA30906B1 (en) COMPOUNDS AND COMPOSITIONS AS QUINHIBITORS OF PROTEINS KINASES
ATE339418T1 (en) THIAZOLE COMPOUNDS THAT ARE SUITABLE AS INHIBITORS OF PROTEIN KINASES
MA29600B1 (en) USE OF SANGLIFEHRIN IN HEPATITIS C VIRUS
MA30539B1 (en) PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES INDUCED BY THE GPR38 RECEPTOR.
MA49673B1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo [7]annulene-2-carboxylic acid and its use for the treatment of cancer
WO2004080422A3 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
BRPI0418384A (en) pharmaceutical compositions and methods for inhibiting fibrous adhesions using various agents
MA29729B1 (en) USE OF 4- (3,4-DICHLOROPHENYL) -1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE FOR THE TREATMENT OF CANCER
PA8691901A1 (en) SOLID PHARMACEUTICAL COMPOSITION THAT INCLUDES 1- (4-CHLORINE-ANILINO) -4- (4-PIRIDIL-METHYL) -FTALAZINE AND A PH MODIFIER
MA31798B1 (en) Organic compounds
TNSN08290A1 (en) USE OF AN INSAPONIFIABLE VEGETABLE PULP EXTRACT IN THE TREATMENT OF SKIN AGING
ATE423100T1 (en) NEW QUINOLINE COMPOUNDS ABLE TO BIND TO THE CB2 RECEPTOR